Technical Articles

Based on the molecular characteristics of GDF-8 inhibiting skeletal muscle growth, global pharmaceutical companies targeting GDF-8 drug development uniformly focus on blocking target signal transduction as the core logic. The current mainstream technical approaches are divided into three categories: neutralizing monoclonal antibodies, which specifically bind to mature GDF-8 ligands to block ligand-receptor binding; soluble ActRIIB fusion proteins (receptor traps), which rely on extracellular domains to capture circulating GDF-8 and activin A; and follistatin analogs, which mimic endogenous inhibitory molecules to competitively bind GDF-8 and inhibit pathway activation.